Short answer
Immunovant, Inc. (IMVT) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$127M
- −15.9% YoY · −4.9% QoQ
- EPS (diluted)
- −$0.72
- +2.7% YoY · −1.4% QoQ
Source: XBRL data from the Immunovant, Inc. (IMVT) Q3 2025 10-Q on SEC EDGAR. USD.
Immunovant, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Clinical-stage company with no quarterly revenue, operating margin, or revenue segments disclosed
- IMVT-1402 programs spanning six indications, including potentially registrational trials in GD, MG, CIDP, D2T RA, and SjD
- Expected top-line results: GD trials 2027, MG 2027, CIDP 2028, SjD 2028, and CLE 2026
- Batoclimab GD follow-up: approximately 80% maintained normalized T3/T4 at Week 48, 8/17 ATD-free
- TED readouts shifted to concurrent disclosure in first half of calendar 2026 amid evolving competitive dynamics
Risk Factors
- New timing risk: evolving competitive dynamics moved concurrent batoclimab TED readouts to first half 2026
- HanAll dispute risk: disagreements over batoclimab plans could trigger arbitration or litigation
- Intellectual-property compliance risk: HanAll breach could terminate rights to develop, manufacture, and sell products
- Operational risk: third-party batoclimab manufacturing disputes could delay development and increase resolution costs
- Regulatory risk: batoclimab’s future development and submissions remain subject to a pending decision after aggregate data review
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Immunovant, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.